[go: up one dir, main page]

SK282438B6 - Vakcínový prostriedok obsahujúci antigény proti malárii - Google Patents

Vakcínový prostriedok obsahujúci antigény proti malárii Download PDF

Info

Publication number
SK282438B6
SK282438B6 SK115-99A SK11599A SK282438B6 SK 282438 B6 SK282438 B6 SK 282438B6 SK 11599 A SK11599 A SK 11599A SK 282438 B6 SK282438 B6 SK 282438B6
Authority
SK
Slovakia
Prior art keywords
protein
malaria
vaccine composition
proteins
falciparum
Prior art date
Application number
SK115-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK11599A3 (en
Inventor
Joseph Cohen
Original Assignee
Smithkline Beecham Biologicals S. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biologicals S. A. filed Critical Smithkline Beecham Biologicals S. A.
Publication of SK11599A3 publication Critical patent/SK11599A3/sk
Publication of SK282438B6 publication Critical patent/SK282438B6/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/015Hemosporidia antigens, e.g. Plasmodium antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK115-99A 1996-08-02 1997-07-31 Vakcínový prostriedok obsahujúci antigény proti malárii SK282438B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9616351.4A GB9616351D0 (en) 1996-08-02 1996-08-02 Vaccine composition
PCT/EP1997/004326 WO1998005355A1 (en) 1996-08-02 1997-07-31 Vaccine composition against malaria

Publications (2)

Publication Number Publication Date
SK11599A3 SK11599A3 (en) 2000-03-13
SK282438B6 true SK282438B6 (sk) 2002-02-05

Family

ID=10797980

Family Applications (1)

Application Number Title Priority Date Filing Date
SK115-99A SK282438B6 (sk) 1996-08-02 1997-07-31 Vakcínový prostriedok obsahujúci antigény proti malárii

Country Status (32)

Country Link
US (2) US20020172692A1 (xx)
EP (2) EP0957933B1 (xx)
JP (1) JP2000517295A (xx)
KR (1) KR20000029747A (xx)
CN (1) CN1241639C (xx)
AP (1) AP1166A (xx)
AR (1) AR008799A1 (xx)
AT (1) ATE394119T1 (xx)
AU (1) AU706303B2 (xx)
BG (1) BG63290B1 (xx)
BR (1) BR9710913A (xx)
CA (1) CA2262402A1 (xx)
CO (1) CO4650186A1 (xx)
CZ (1) CZ290826B6 (xx)
DE (1) DE69738672D1 (xx)
DZ (1) DZ2283A1 (xx)
EA (1) EA002167B1 (xx)
GB (1) GB9616351D0 (xx)
ID (1) ID17860A (xx)
IL (1) IL128318A (xx)
MA (1) MA24291A1 (xx)
MY (1) MY116128A (xx)
NO (1) NO319844B1 (xx)
OA (1) OA10969A (xx)
PE (1) PE97298A1 (xx)
PL (1) PL188741B1 (xx)
SK (1) SK282438B6 (xx)
TR (1) TR199900195T2 (xx)
UA (1) UA68336C2 (xx)
UY (1) UY24654A1 (xx)
WO (1) WO1998005355A1 (xx)
ZA (1) ZA976815B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915204D0 (en) * 1999-06-29 1999-09-01 Smithkline Beecham Biolog Vaccine
RU2356577C9 (ru) 2002-10-23 2009-08-10 Глаксосмитклайн Байолоджикалс С.А. Способы вакцинации против малярии
KR101176673B1 (ko) * 2003-12-01 2012-08-23 가부시키가이샤 메이지 앤지오텐신 변환 효소 저해 팹티드
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
AU2006274647B2 (en) * 2005-08-02 2013-01-10 Novartis Vaccines And Diagnostics Srl Reducing interference between oil-containing adjuvants and surfactant-containing antigens
GB0614254D0 (en) * 2006-07-18 2006-08-30 Smithkline Beecham Biolog Vaccine
KR20090094213A (ko) * 2006-07-18 2009-09-04 글락소스미스클라인 바이오로지칼즈 에스.에이. 말라리아 백신
EP2066344B2 (en) 2006-09-07 2016-06-29 GlaxoSmithKline Biologicals S.A. Inactivated Poliovirus combination vaccine
UY31285A1 (es) 2007-08-13 2009-03-31 Vacunas
AU2008339980A1 (en) * 2007-12-21 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccines for malaria
KR20100111281A (ko) 2007-12-24 2010-10-14 글락소스미스클라인 바이오로지칼즈 에스.에이. 말라리아 백신
WO2010002818A2 (en) * 2008-06-30 2010-01-07 United States Army As Represented By The Secretar Of The Army Malaria vaccine of self-assembling polypeptide nanoparticles
EP2451478A4 (en) * 2009-11-05 2013-11-20 Us Navy PLASMODIUM FALCIPARUM SPOROZOITE AND LIVERPHASE ANTIGENS THEREWITH
AU2011310838B2 (en) 2010-09-27 2015-11-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
CN104338129B (zh) * 2013-07-26 2017-05-24 中国科学院上海巴斯德研究所 雷帕霉素作为疫苗佐剂的用途及制备方法
EP3551222B1 (en) 2016-12-07 2024-08-07 GlaxoSmithKline Biologicals SA Process for making a liposome composition comprising a saponin
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB2600652B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel compositions
WO2019106192A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0071705B1 (en) * 1981-05-21 1989-11-23 The Wellcome Foundation Limited Protozoal antigen
PT82282B (pt) * 1985-03-28 1988-02-17 Univ New York Processo de preparacao de um conjugado de proteina de suporte-antigeno imunogenico para uso como vacina contra malaria
GB8819209D0 (en) * 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
GB9012580D0 (en) * 1990-06-06 1990-07-25 Univ Nijmegen Novel protein
FR2679776A1 (fr) * 1991-07-31 1993-02-05 Pasteur Institut Melange de constituants peptidiques ayant des proprietes vaccinantes contre le paludisme, notamment du a plasmodium falciparum.
SG48390A1 (en) * 1991-11-16 1998-04-17 Smithkline Beecham Biolog Hybrid protein between cs from plasmodium and hbs ag
US6169171B1 (en) * 1992-02-27 2001-01-02 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBSAG
DK0761231T3 (da) * 1992-06-25 2000-05-08 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM368994A0 (en) * 1994-02-04 1994-02-24 Saramane Pty Ltd Malaria merozoite antigen subunit vaccine
FR2744723A1 (fr) * 1996-02-14 1997-08-14 Pasteur Institut Proteine recombinante contenant un fragment c-terminal d'une proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques
FR2744724B1 (fr) * 1996-02-14 2002-08-02 Pasteur Institut Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques

Also Published As

Publication number Publication date
CO4650186A1 (es) 1998-09-03
IL128318A (en) 2002-04-21
EA002167B1 (ru) 2002-02-28
PL188741B1 (pl) 2005-04-29
ZA976815B (en) 1998-05-11
OA10969A (en) 2003-03-04
WO1998005355A1 (en) 1998-02-12
JP2000517295A (ja) 2000-12-26
AP1166A (en) 2003-06-30
ATE394119T1 (de) 2008-05-15
GB9616351D0 (en) 1996-09-11
US20020172692A1 (en) 2002-11-21
EA199900069A1 (ru) 1999-10-28
ID17860A (id) 1998-01-29
CN1231613A (zh) 1999-10-13
UY24654A1 (es) 2001-08-27
PE97298A1 (es) 1999-02-14
CZ290826B6 (cs) 2002-10-16
DE69738672D1 (de) 2008-06-19
AU4204097A (en) 1998-02-25
BG103141A (en) 1999-08-31
CN1241639C (zh) 2006-02-15
IL128318A0 (en) 2000-01-31
EP1623720A2 (en) 2006-02-08
NO990464L (no) 1999-02-01
TR199900195T2 (xx) 1999-04-21
DZ2283A1 (fr) 2002-12-25
UA68336C2 (en) 2004-08-16
EP0957933A1 (en) 1999-11-24
AU706303B2 (en) 1999-06-10
CA2262402A1 (en) 1998-02-12
MA24291A1 (fr) 1998-04-01
EP0957933B1 (en) 2008-05-07
AR008799A1 (es) 2000-02-23
KR20000029747A (ko) 2000-05-25
MY116128A (en) 2003-11-28
AP9901448A0 (en) 1999-03-31
EP1623720A3 (en) 2006-02-22
SK11599A3 (en) 2000-03-13
NO990464D0 (no) 1999-02-01
NO319844B1 (no) 2005-09-19
PL331424A1 (en) 1999-07-19
BG63290B1 (bg) 2001-09-28
US20060292170A1 (en) 2006-12-28
BR9710913A (pt) 1999-08-17
CZ29299A3 (cs) 1999-06-16

Similar Documents

Publication Publication Date Title
US20060292170A1 (en) Vaccine Composition Against Malaria
JP5486802B2 (ja) 抗マラリアワクチン
WO2009080715A2 (en) Vaccines for malaria
US20030133944A1 (en) Vaccine composition against malaria
US20110262469A1 (en) Malaria vaccine based on fragments and combination of fragments of the cs protein of plasmodium vivax
EP0241725B1 (en) Improvements in and relating to vaccines
Heppner et al. Adjuvanted RTS, S and other protein-based pre-erythrocytic stage malaria vaccines